Advertisement
Advertisement
U.S. markets closed
S&P Futures
4,075.25 -9.00 (-0.22%) Dow Futures
33,990.00 -56.00 (-0.16%) Nasdaq Futures
12,190.25 -32.00 (-0.26%) Russell 2000 Futures
1,914.60 -4.90 (-0.26%) Crude Oil
80.02 +0.34 (+0.43%) Gold
1,942.10 -3.50 (-0.18%)
At close: 04:00PM EST
After hours:
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 137.54 |
| Open | 137.95 |
| Bid | 138.50 x 1000 |
| Ask | 140.00 x 1300 |
| Day's Range | 137.57 - 138.81 |
| 52 Week Range | 94.75 - 144.78 |
| Volume | |
| Avg. Volume | 1,405,109 |
| Market Cap | 310.582B |
| Beta (5Y Monthly) | 0.35 |
| PE Ratio (TTM) | 40.61 |
| EPS (TTM) | 3.40 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.60 (1.16%) |
| Ex-Dividend Date | Aug 12, 2022 |
| 1y Target Est | 140.37 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
0% Est. Return
Subscribe to Yahoo Finance Plus to view Fair Value for NVO
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Novo Nordisk A/SAnalyst Report: Novo Nordisk A/SWith almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.RatingFair ValueEconomic Moat20 days agoMorningstar
- Zacks
Weibo and Viasat have been highlighted as Zacks Bull and Bear of the Day
Weibo and Viasat are part of the Zacks Bull and Bear of the Day article.
- Zacks
Eli Lilly (LLY) to Report Q4 Earnings: What's in the Cards?
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) fourth-quarter sales.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2023 Yahoo. All rights reserved.
